WallStreetZenWallStreetZen

NASDAQ: TVTX
Travere Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Travere Therapeutics revenue was $233.18M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $74.8M, up 18.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TVTX annual revenue was $233.2M, with 60.5% growth year-over-year.

TVTX past revenue growth

How has TVTX's revenue growth performed historically?

Company
60.55%
Industry
443.32%
Market
20.2%
TVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TVTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TVTX revenue history

Current Revenue
$233.2M
Current Earnings
-$321.5M
Current Profit Margin
-137.9%

Be the first to know when TVTX announces revenue.

TVTX Revenue History By Year

TVTX Yearly RevenueTVTX RevenueTVTX ChangeTVTX Revenue Growth
2024-12-31$233.18M$87.94M+60.55%
2023-12-31$145.24M$35.78M+32.69%
2022-12-31$109.46M-$22.38M-16.97%
2021-12-31$131.84M-$66.49M-33.52%
2020-12-31$198.32M$22.98M+13.11%
2019-12-31$175.34M$11.09M+6.75%
2018-12-31$164.25M$9.31M+6.01%
2017-12-31$154.94M$21.35M+15.98%
2016-12-31$133.59M$33.70M+33.74%
2015-12-31$99.89M$71.69M+254.19%
2014-12-31$28.20MN/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A

1 of 1

Travere Therapeutics Revenue FAQ

What was TVTX's revenue last quarter?

On Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q4 2024 revenue of $74.79 million up 65.98% year over year. In the same quarter last year, Travere Therapeutics's revenue was $45.06 million.

What was Travere Therapeutics's revenue in 2024?

Travere Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $233.18 million, a 60.55% increase year over year.

How much does Travere Therapeutics make in a day?

Based on Travere Therapeutics annual revenue for the past five years, TVTX makes an average of $448,235.62 per day.

What was Travere Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Travere Therapeutics's revenue has grown 60.55% year over year. This is 382.77 percentage points lower than the US Biotechnology industry revenue growth rate of 443.32%. Travere Therapeutics's revenue in the past year totaled $233.18 million.

How much does Travere Therapeutics make in a year?

Travere Therapeutics's revenue by year for the past five years is:
  • Travere Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $233.18 million, a 60.55% increase year over year.
  • Travere Therapeutics's annual revenue for Dec 31, 2023 was $145.24 million, a 32.69% increase from 2022.
  • Travere Therapeutics's annual revenue for 2022 was $109.46 million, a 16.97% decrease from 2021.
  • Travere Therapeutics's annual revenue for 2021 was $131.84 million, a 33.52% decrease from 2020.
  • Travere Therapeutics's annual revenue for 2020 was $198.32 million, a 13.11% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.